The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing low demand.
It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
The agency says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.
It is distributing two mRNA vaccines—made by Pfizer-BioNTech and Moderna—that are approved for adults and children six months and older.
Both COVID-19 vaccines have been reformulated to target the recently circulating KP.2 subvariant of Omicron….